Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian CancerSarah P. Blagden, Hani Gabra, Euan A. Stronach et al.|Clinical Cancer Research|2018Cited by 66
Pharmacokinetic (PK)/pharmacodynamic (PD) analysis of escalating repeat doses of the AKT inhibitor GSK2141795 (GSK795) in patients (pts) with ovarian cancer.Hatice Güngör, Hani Gabra, Azeem Saleem et al.|Journal of Clinical Oncology|2011Cited by 14
Phase I/II dose-escalation and expansion study of afuresertib + carboplatin and paclitaxel in recurrent ovarian cancer.Sarah P. Blagden, Tarek Meniawy, Hani Gabra et al.|Journal of Clinical Oncology|2016Cited by 4
1064O ICON8B: GCIG phase III randomised trial comparing first-line weekly dose-dense chemotherapy + bevacizumab to three-weekly chemotherapy + bevacizumab in high-risk stage III-IV epithelial ovarian cancer (EOC): Final overall survival (OS) analysisA. Clamp, JA Ledermann, Iain A. McNeish et al.|Annals of Oncology|2025Cited by 3
ICON8B: GCIG phase III randomised trial comparing first-line weekly dose-dense chemotherapy + bevacizumab to three-weekly chemotherapy + bevacizumab in high-risk stage III-IV epithelial ovarian cancer: final overall survival (OS) analysisA. Clamp, Jonathan A. Ledermann, Domenico Radice et al.|International Journal of Gynecological Cancer|2026Cited by 1